Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • BW TV
  • Subscribe to Print
BW Businessworld

Lupin Gets US Nod To Market Tablets Used For Treatment Of HIV Virus

According to a company statement, tentative approval was received for Abacavir Sulfate and Lamivudine tablets

Photo Credit :

1479903703_5GM33H_Pharma_US_FDA_Reu.jpg

Pharma major Lupin has received tentative approval for its Abacavir Sulfate and Lamivudine tablets from the USFDA to market generic version of ViiV Healthcare company's Epzicom tablets.

"Lupin's Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare company's Epzicom tablets, 600 mg/300 mg. Abacavir Sulfate and Lamivudine tablets, 600 mg/300 mg in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection," a company statement said.

The statement further said, "We have received tentative approval from USFDA for Abacavir Sulfate and Lamivudine tablets, to market a generic version of ViiV Healthcare company's Epzicom tablets."

Epzicom tablets had the US sales of $426 million.

The company is a significant player in cardiovascular, diabetology, asthma, paediatric and anti-infective space and holds global leadership position in the Anti-TB segment.


Tags assigned to this article:
usfda lupin pharmaceuticals